Deena Godfrey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deena Godfrey has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Ann-Christine Duhaime
Massachusetts General Hospital
3 shared publicationsCarla Fortes
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
2 shared publicationsMichael Bambrick
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications- Aaron Frank Struck
Washington University in St. Louis
1 shared publication - Aditya Gupta
Department of Neurology, Beth Israel Deaconess Medical Center , Boston, MA
1 shared publication Alcy Torres
Department of Pediatrics, Boston Medical Center, Boston, Massachusetts, USA
1 shared publication
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Research Square
Patterns and Clinical Predictors of Antiseizure Medication Use in Pediatric Traumatic Brain Injury
Objective Current guidelines recommend the use of antiseizure medications (ASM) in pediatric patients with severe traumatic brain injury (TBI). This is based on low-quality evidence and can lead to variability in practice and over-prescription of medications. To understand factors influencing ASM prescription in pediatric TBI, we examined clinical variables associated with inpatient and discharge ASM prescription. Methods Multi-center, retrospective cohort study of patients aged 0 to 21 years, admitted with TBI to the intensive care units at two Level I trauma centers, from 2016 through 2024. Obtained demographic and clinical information from chart review. Neuroimaging and electroencephalogram findings were extracted from reports. Primary outcome measure was ASM administration during inpatient hospitalization. Secondary outcome measure was prescription of ASMs at discharge. We developed multivariable logistic regression models to identify factors associated with inpatient and discharge ASM prescription, and report adjusted odds ratios (OR) with 95% confidence intervals (CI). Results 467 patients met inclusion criteria. 287 (61%) patients were given an ASM during their hospitalization, and 159 (34%) patients were discharged from the hospital on an ASM. Factors associated with higher likelihood of inpatient ASM prescription include intracranial injury on imaging (OR 57, 95% CI 24–156), moderate Glasgow Coma Scale score of 9 to 12 (OR 21, 95% CI 2.4–354), neurology/neurosurgery admission (OR 11, 95% CI 3.1–42), and immediate seizures (OR 3.6, 95% CI 0.77-23). Clinical factors associated with greater likelihood of discharge ASM prescription were neuroimaging abnormalities (OR 8.5, 95% CI 4.0–20), immediate seizures (OR 6.1, 95% CI 1.9–22), and neurology/neurosurgery admission (OR 2.1, 95% CI 0.71–6.8). Conclusions Neuroimaging abnormalities, seizures, and admission to neurology or neurosurgery services were associated with greater likelihood of ASM prescription during hospitalization and at discharge. Future studies are needed to determine whether ASM prescription improves outcomes and optimize ASM use.
- 26 August 2026
- Published by Springer Nature in Research Square
Open AccessPatterns and Clinical Predictors of Antiseizure Medication Use in Pediatric Traumatic Brain Injury
Objective Current guidelines recommend the use of antiseizure medications (ASM) in pediatric patients with severe traumatic brain injury (TBI). This is based on low-quality evidence and can lead to variability in practice and over-prescription of medications. To understand factors influencing ASM prescription in pediatric TBI, we examined clinical variables associated with inpatient and discharge ASM prescription. Methods Multi-center, retrospective cohort study of patients aged 0 to 21 years, admitted with TBI to the intensive care units at two Level I trauma centers, from 2016 through 2024. Obtained demographic and clinical information from chart review. Neuroimaging and electroencephalogram findings were extracted from reports. Primary outcome measure was ASM administration during inpatient hospitalization. Secondary outcome measure was prescription of ASMs at discharge. We developed multivariable logistic regression models to identify factors associated with inpatient and discharge ASM prescription, and report adjusted odds ratios (OR) with 95% confidence intervals (CI). Results 467 patients met inclusion criteria. 287 (61%) patients were given an ASM during their hospitalization, and 159 (34%) patients were discharged from the hospital on an ASM. Factors associated with higher likelihood of inpatient ASM prescription include intracranial injury on imaging (OR 57, 95% CI 24–156), moderate Glasgow Coma Scale score of 9 to 12 (OR 21, 95% CI 2.4–354), neurology/neurosurgery admission (OR 11, 95% CI 3.1–42), and immediate seizures (OR 3.6, 95% CI 0.77-23). Clinical factors associated with greater likelihood of discharge ASM prescription were neuroimaging abnormalities (OR 8.5, 95% CI 4.0–20), immediate seizures (OR 6.1, 95% CI 1.9–22), and neurology/neurosurgery admission (OR 2.1, 95% CI 0.71–6.8). Conclusions Neuroimaging abnormalities, seizures, and admission to neurology or neurosurgery services were associated with greater likelihood of ASM prescription during hospitalization and at discharge. Future studies are needed to determine whether ASM prescription improves outcomes and optimize ASM use.
- 7 April 2026
- Published by Elsevier in Seminars in Pediatric Neurology
- Vol. 58, 101288
Pediatric concussion beyond sports: Falls, play, and everyday activities
- 7 April 2026
- Published by Elsevier in Seminars in Pediatric Neurology
- Vol. 58, 101288
Pediatric concussion beyond sports: Falls, play, and everyday activities
- 3 November 2025
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 43 (7-8) , 544-558
Association Between Plasma Glial Fibrillary Acidic Protein, Ubiquitin Carboxy-Terminal Hydrolase-L1, S100B, and High-Sensitivity C-Reactive Protein Levels, Clinical Findings, and Imaging Abnormalities in Children with Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study
Blood-based biomarkers have shown utility in discriminating adult patients with and without traumatic brain injury (TBI). Biomarker levels vary with severity, time since injury, and imaging findings (computed tomography [CT] and magnetic resonance imaging [MRI]). However, the association of specific biomarkers with clinical and imaging findings in children across the age spectrum and with different injury severities and presentations is not fully understood. To better characterize biomarker and clinical associations, we studied pediatric blood biomarker patterns within the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study (ClinicalTrials.gov #NCT02119182). TRACK-TBI is an observational multisite study that prospectively enrolled TBI patients across the lifespan and injury spectrum, from 2014 through 2018. Two centers enrolled children (ages 0–17 years). All participants underwent a head CT or MRI at the discretion of treating clinicians as part of acute clinical care, and the majority underwent a study MRI 2 weeks after injury. For this TRACK-TBI pediatric cohort, blood sampling was optional with informed consent provided by guardians. For the purposes of this study, only pediatric subjects with study-specific neuroimaging and plasma biomarkers were included. Plasma biomarkers assessed included glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), S100 calcium-binding protein B (S100B), neuron-specific enolase (NSE), and high-sensitivity C-reactive protein (hsCRP). Biomarker levels were compared between participants with and without radiographical traumatic intracranial findings (day-of-injury CT-positive versus CT-negative and 2-week study MRI-positive versus MRI-negative) and between participants with different clinical indices of injury. Of 158 pediatric participants, 75 consented to blood collection and underwent biomarker analysis. Of these, 65 had acute CT scans (within 24 h of injury) and 43 had standardized study-related MRI scans at 2 weeks (±3 days) from injury; thus, 70 subjects had biomarker levels and study-reviewed CTs and/or MRIs and are included in the present analysis. Univariate analyses showed significant differences in plasma GFAP, UCHL1, S100B, and hsCRP with respect to time since injury and CT findings. GFAP levels differed by Glasgow Coma Scale (GCS) severities and MRI findings; S100B levels differed by GCS and loss of consciousness. Multivariable linear regression models confirmed a significant association of GFAP, UCH-L1, and S100B levels with CT-positive findings and a significant association of GFAP with 2-week MRI-positive findings. Among the biomarkers evaluated in our study, GFAP was the strongest predictor of imaging findings using receiver operating characteristic analysis. Significant age effects were seen for S100B and NSE, with higher values in younger children. Multivariable associations were observed for specific day-of-injury plasma biomarkers and radiographical traumatic intracranial findings on CT and MRI in children with acute TBI. These biomarkers have potential utility to aid in TBI screening by helping to triage which patients are likely to have intracranial findings on neuroimaging.
- 3 November 2025
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 43 (7-8) , 544-558
Association Between Plasma Glial Fibrillary Acidic Protein, Ubiquitin Carboxy-Terminal Hydrolase-L1, S100B, and High-Sensitivity C-Reactive Protein Levels, Clinical Findings, and Imaging Abnormalities in Children with Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study
Blood-based biomarkers have shown utility in discriminating adult patients with and without traumatic brain injury (TBI). Biomarker levels vary with severity, time since injury, and imaging findings (computed tomography [CT] and magnetic resonance imaging [MRI]). However, the association of specific biomarkers with clinical and imaging findings in children across the age spectrum and with different injury severities and presentations is not fully understood. To better characterize biomarker and clinical associations, we studied pediatric blood biomarker patterns within the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study (ClinicalTrials.gov #NCT02119182). TRACK-TBI is an observational multisite study that prospectively enrolled TBI patients across the lifespan and injury spectrum, from 2014 through 2018. Two centers enrolled children (ages 0–17 years). All participants underwent a head CT or MRI at the discretion of treating clinicians as part of acute clinical care, and the majority underwent a study MRI 2 weeks after injury. For this TRACK-TBI pediatric cohort, blood sampling was optional with informed consent provided by guardians. For the purposes of this study, only pediatric subjects with study-specific neuroimaging and plasma biomarkers were included. Plasma biomarkers assessed included glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), S100 calcium-binding protein B (S100B), neuron-specific enolase (NSE), and high-sensitivity C-reactive protein (hsCRP). Biomarker levels were compared between participants with and without radiographical traumatic intracranial findings (day-of-injury CT-positive versus CT-negative and 2-week study MRI-positive versus MRI-negative) and between participants with different clinical indices of injury. Of 158 pediatric participants, 75 consented to blood collection and underwent biomarker analysis. Of these, 65 had acute CT scans (within 24 h of injury) and 43 had standardized study-related MRI scans at 2 weeks (±3 days) from injury; thus, 70 subjects had biomarker levels and study-reviewed CTs and/or MRIs and are included in the present analysis. Univariate analyses showed significant differences in plasma GFAP, UCHL1, S100B, and hsCRP with respect to time since injury and CT findings. GFAP levels differed by Glasgow Coma Scale (GCS) severities and MRI findings; S100B levels differed by GCS and loss of consciousness. Multivariable linear regression models confirmed a significant association of GFAP, UCH-L1, and S100B levels with CT-positive findings and a significant association of GFAP with 2-week MRI-positive findings. Among the biomarkers evaluated in our study, GFAP was the strongest predictor of imaging findings using receiver operating characteristic analysis. Significant age effects were seen for S100B and NSE, with higher values in younger children. Multivariable associations were observed for specific day-of-injury plasma biomarkers and radiographical traumatic intracranial findings on CT and MRI in children with acute TBI. These biomarkers have potential utility to aid in TBI screening by helping to triage which patients are likely to have intracranial findings on neuroimaging.
- Open Access
- 10 June 2025
- Published by Society for Neuroscience in eneuro
- Vol. 12 (6)
Release of Extracellular Matrix Components after Human Traumatic Brain Injury
Animal studies and human tissue experiments have demonstrated that traumatic brain injury (TBI) causes damage to the extracellular matrix (ECM). To test the hypothesis that TBI causes disruption of sulfated glycosaminoglycan (sGAG) in the ECM, we measured levels of sGAG in the cerebrospinal fluid (CSF), blood, and urine, in patients with severe TBI in the acute postinjury period. Samples of CSF, blood, and urine were obtained within 72 h of injury in patients who received external ventricular drains as part of their treatment of severe TBI. Levels of chondroitin and heparan sGAGs were measured, along with their disaccharide constituents. Demographic information, presence of polytrauma, brain injury load, and distance of radiologically visible parenchymal injury from the ventricle were analyzed for correlation with total subtype sGAG levels. Levels were measured in 14 patients ranging in age from 17 to 90 years. CSF sGAG levels were variable among patients, with higher sGAG levels in plasma compared with CSF. Patients with polytrauma had nonsignificantly higher blood sGAG compared with patients with isolated head injury. Subcategories of CSF sGAG levels correlated with distance from the ventricle of parenchymal injury but not with brain injury load. This study is the first to measure sGAG levels in ventricular CSF and the first to analyze levels in TBI. These data demonstrate the elevation locally of intracranial sGAGs after severe TBI and suggest rapid local metabolism of these breakdown products. The consequences of ECM breakdown may provide unique therapeutic and preventive avenues to mitigate postinjury sequelae.
- 10 June 2025
- Published by Society for Neuroscience in eneuro
- Vol. 12 (6)
Open AccessRelease of Extracellular Matrix Components after Human Traumatic Brain Injury
Animal studies and human tissue experiments have demonstrated that traumatic brain injury (TBI) causes damage to the extracellular matrix (ECM). To test the hypothesis that TBI causes disruption of sulfated glycosaminoglycan (sGAG) in the ECM, we measured levels of sGAG in the cerebrospinal fluid (CSF), blood, and urine, in patients with severe TBI in the acute postinjury period. Samples of CSF, blood, and urine were obtained within 72 h of injury in patients who received external ventricular drains as part of their treatment of severe TBI. Levels of chondroitin and heparan sGAGs were measured, along with their disaccharide constituents. Demographic information, presence of polytrauma, brain injury load, and distance of radiologically visible parenchymal injury from the ventricle were analyzed for correlation with total subtype sGAG levels. Levels were measured in 14 patients ranging in age from 17 to 90 years. CSF sGAG levels were variable among patients, with higher sGAG levels in plasma compared with CSF. Patients with polytrauma had nonsignificantly higher blood sGAG compared with patients with isolated head injury. Subcategories of CSF sGAG levels correlated with distance from the ventricle of parenchymal injury but not with brain injury load. This study is the first to measure sGAG levels in ventricular CSF and the first to analyze levels in TBI. These data demonstrate the elevation locally of intracranial sGAGs after severe TBI and suggest rapid local metabolism of these breakdown products. The consequences of ECM breakdown may provide unique therapeutic and preventive avenues to mitigate postinjury sequelae.
- Open Access
- 9 September 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 149, 39-43
Monogenic Causes of Cerebrovascular Disease in Childhood: A Case Series
- 9 September 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 149, 39-43
Open AccessMonogenic Causes of Cerebrovascular Disease in Childhood: A Case Series
- 5 May 2021
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 42 (5) , 612-614
A 7-year old female with arthrogryposis multiplex congenita, Duane retraction syndrome, and Marcus Gunn phenomenon due to a ZC4H2 gene mutation: a clinical presentation of the Wieacker-Wolff syndrome
Background: Duane retraction syndrome and arthrogryposis multiplex congenita have an incidence of approximately 1:1500–1:3000 live births. However, the association of these two entities with a Marcus-Gunn might be a rare and, until now, under-recognized clinical presentation of the Wieacker-Wolff Syndrome. Patient and methods: We report a 7-year-old female with dysmorphic features, global developmental delay, arthrogryposis multiplex congenita (AMC), Duane retraction syndrome (DRS), and unilateral Marcus Gunn jaw winking. Results: Whole Exome Sequencing showed a de novo premature stop codon in ZC4H2. Extensive genetic and metabolic work was negative otherwise and Brain MRI showed delayed non-specific myelination abnormalities. She continues to have significant delays but does not have regression, seizures or other neurological complications. She has required a multidisciplinary approach for the management of her multiple contractures. Conclusion: This case confirms ZC4H2 as a cause of syndromic DRS and extends the ZC4H2 phenotype to include Marcus Gunn jaw winking.
- 5 May 2021
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 42 (5) , 612-614
A 7-year old female with arthrogryposis multiplex congenita, Duane retraction syndrome, and Marcus Gunn phenomenon due to a ZC4H2 gene mutation: a clinical presentation of the Wieacker-Wolff syndrome
Background: Duane retraction syndrome and arthrogryposis multiplex congenita have an incidence of approximately 1:1500–1:3000 live births. However, the association of these two entities with a Marcus-Gunn might be a rare and, until now, under-recognized clinical presentation of the Wieacker-Wolff Syndrome. Patient and methods: We report a 7-year-old female with dysmorphic features, global developmental delay, arthrogryposis multiplex congenita (AMC), Duane retraction syndrome (DRS), and unilateral Marcus Gunn jaw winking. Results: Whole Exome Sequencing showed a de novo premature stop codon in ZC4H2. Extensive genetic and metabolic work was negative otherwise and Brain MRI showed delayed non-specific myelination abnormalities. She continues to have significant delays but does not have regression, seizures or other neurological complications. She has required a multidisciplinary approach for the management of her multiple contractures. Conclusion: This case confirms ZC4H2 as a cause of syndromic DRS and extends the ZC4H2 phenotype to include Marcus Gunn jaw winking.
- 5 March 2021
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 25 (8) , 1697-1703
Triad of hypovitaminosis A, hyperostosis, and optic neuropathy in males with autism spectrum disorders
Persons with autism spectrum disorder (ASD) can have restrictive diets due to stereotyped behaviors. These restrictive diets can manifest with nutritional deficiencies, such as Vitamin A deficiency...
- 5 March 2021
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 25 (8) , 1697-1703
Triad of hypovitaminosis A, hyperostosis, and optic neuropathy in males with autism spectrum disorders
Persons with autism spectrum disorder (ASD) can have restrictive diets due to stereotyped behaviors. These restrictive diets can manifest with nutritional deficiencies, such as Vitamin A deficiency...